Fulcrum Therapeutics is a biopharmaceutical company developing drug candidates targeting genetically determined conditions with significant treatment gaps. The company's lead program, pociredir, is being tested in early-stage trials for sickle cell disease and beta-thalassemia by increasing fetal hemoglobin production, while its pipeline includes research programs addressing diamond-blackfan anemia, bone marrow failure disorders, and fibrotic conditions. The company operates under a licensing agreement with CAMP4 that provides access to small molecule compounds and related intellectual property for research and commercialization.

entry readiness 49 · WEAK SETUP · exit proximity 0

Value area 3.46–3.91 · 43% of 120d volume overhead · moderate overhead